AU2009290612B2 - Methods of treatment of hyperuricemia and associated disease states - Google Patents

Methods of treatment of hyperuricemia and associated disease states Download PDF

Info

Publication number
AU2009290612B2
AU2009290612B2 AU2009290612A AU2009290612A AU2009290612B2 AU 2009290612 B2 AU2009290612 B2 AU 2009290612B2 AU 2009290612 A AU2009290612 A AU 2009290612A AU 2009290612 A AU2009290612 A AU 2009290612A AU 2009290612 B2 AU2009290612 B2 AU 2009290612B2
Authority
AU
Australia
Prior art keywords
uric acid
inositol
scyllo
patient
day
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2009290612A
Other languages
English (en)
Other versions
AU2009290612A1 (en
Inventor
Jesse Cedarbaum
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Transition Therapeutics Ireland Ltd
Original Assignee
Transition Therapeutics Ireland Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Transition Therapeutics Ireland Ltd filed Critical Transition Therapeutics Ireland Ltd
Publication of AU2009290612A1 publication Critical patent/AU2009290612A1/en
Application granted granted Critical
Publication of AU2009290612B2 publication Critical patent/AU2009290612B2/en
Assigned to TRANSITION THERAPEUTICS IRELAND LIMITED reassignment TRANSITION THERAPEUTICS IRELAND LIMITED Request for Assignment Assignors: ELAN PHARMACEUTICALS, INC.
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/04—Drugs for disorders of the urinary system for urolithiasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Obesity (AREA)
  • Toxicology (AREA)
  • Vascular Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2009290612A 2008-09-15 2009-09-15 Methods of treatment of hyperuricemia and associated disease states Active AU2009290612B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US9702308P 2008-09-15 2008-09-15
US61/097,023 2008-09-15
PCT/US2009/056985 WO2010031051A1 (en) 2008-09-15 2009-09-15 Methods of treatment of hyperuricemia and associated disease states

Publications (2)

Publication Number Publication Date
AU2009290612A1 AU2009290612A1 (en) 2010-03-18
AU2009290612B2 true AU2009290612B2 (en) 2015-05-14

Family

ID=41319433

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2009290612A Active AU2009290612B2 (en) 2008-09-15 2009-09-15 Methods of treatment of hyperuricemia and associated disease states

Country Status (9)

Country Link
US (1) US8748496B2 (enExample)
EP (1) EP2349280B1 (enExample)
JP (1) JP5685192B2 (enExample)
AR (1) AR073514A1 (enExample)
AU (1) AU2009290612B2 (enExample)
CA (1) CA2737163C (enExample)
ES (1) ES2521674T3 (enExample)
TW (1) TW201016208A (enExample)
WO (2) WO2010031051A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7521481B2 (en) * 2003-02-27 2009-04-21 Mclaurin Joanne Methods of preventing, treating and diagnosing disorders of protein aggregation
PT3321359T (pt) 2005-04-11 2021-03-11 Horizon Pharma Rheumatology Llc Formas variantes de urato-oxidase e a sua utilização
SG176897A1 (en) 2009-06-25 2012-01-30 Savient Pharmaceuticals Inc Methods and kits for predicting infusion reaction risk and antibody-mediated loss of response by monitoring serum uric acid during pegylated uricase therapy
CN102726721A (zh) * 2011-12-21 2012-10-17 聂存良 一种平衡性的微量元素排铅口服液
US20160303050A1 (en) * 2015-04-20 2016-10-20 Twi Biotechnology, Inc. Formulations containing diacerein and methods of lowering blood levels of uric acid using the same
WO2018089808A1 (en) 2016-11-11 2018-05-17 Horizon Pharma Rheumatology Llc Combination therapies of prednisone and uricase molecules and uses thereof
CN109666687B (zh) * 2018-12-14 2020-08-04 艾美科健（中国）生物医药有限公司 一种生物转化生产鲨肌醇的大肠埃希氏菌工程菌株及其构建方法和应用
WO2020160325A1 (en) 2019-01-30 2020-08-06 Horizon Pharma Rheumatology Llc Reducing immunogenicity to pegloticase
US12121566B2 (en) 2019-01-30 2024-10-22 Horizon Therapeutics Usa, Inc. Methods for treating gout
US12269875B2 (en) 2023-08-03 2025-04-08 Jeff R. Peterson Gout flare prevention methods using IL-1BETA blockers

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998057620A2 (en) * 1997-06-16 1998-12-23 Cedars-Sinai Medical Center Inositol for modulation of immune response
WO2006053428A1 (en) * 2004-11-17 2006-05-26 Joanne Mclaurin Compositions comprising scyllo-inositol derivatives and methods to treat disorders of protein aggregation
US20080200437A1 (en) * 2006-12-29 2008-08-21 Jean-Marie Lehn Cyclitols and Their Derivatives and Their Therapeutic Applications

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998057620A2 (en) * 1997-06-16 1998-12-23 Cedars-Sinai Medical Center Inositol for modulation of immune response
WO2006053428A1 (en) * 2004-11-17 2006-05-26 Joanne Mclaurin Compositions comprising scyllo-inositol derivatives and methods to treat disorders of protein aggregation
US20080200437A1 (en) * 2006-12-29 2008-08-21 Jean-Marie Lehn Cyclitols and Their Derivatives and Their Therapeutic Applications

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
SPEIKER LE, et al., European Journal of Heart Failure, (2002), Vol 4, pp 403-410. *

Also Published As

Publication number Publication date
US8748496B2 (en) 2014-06-10
AU2009290612A1 (en) 2010-03-18
CA2737163C (en) 2019-03-12
EP2349280A1 (en) 2011-08-03
TW201016208A (en) 2010-05-01
US20100152305A1 (en) 2010-06-17
ES2521674T3 (es) 2014-11-13
AR073514A1 (es) 2010-11-10
WO2010031051A1 (en) 2010-03-18
JP5685192B2 (ja) 2015-03-18
EP2349280B1 (en) 2014-07-30
CA2737163A1 (en) 2010-03-18
JP2012502914A (ja) 2012-02-02
WO2010031061A1 (en) 2010-03-18

Similar Documents

Publication Publication Date Title
AU2009290612B2 (en) Methods of treatment of hyperuricemia and associated disease states
TWI415599B (zh) Ｐｄｅiii抑制劑用於降低罹患心臟衰竭之哺乳動物之心臟大小之用途
CA2907079C (en) Combination of canagliflozin and probenecid for the treatment of hyperuricemia
WO2012050589A1 (en) Methods for treating hyperuricemia and related diseases
TW201615221A (zh) 炎症用藥臨床新應用
EP4321157A2 (en) New use of a combination of an angiotensin receptor blocker (arb) with a neutral endopeptidase inhibitor (nepi)
KR20180127493A (ko) 승모판 질환으로 인한 무증상 심부전이 있는 환자에서 심장 크기의 감소 및/또는 임상적 증상 개시의 지연을 위한 피모벤단의 용도
US8399518B2 (en) Administration of 3,5-diiodothyropropionic acid for stimulating weight loss, and/or lowering triglyceride levels, and/or treatment of metabolic syndrome
AU2013247291A1 (en) Lercanidipine hydrochloride and losartan potassium compound preparation and preparation method thereof
WO2020193652A1 (en) Canagliflozin for the treatment of diabetic patients with chronic kidney disease
CN101229372A (zh) 一种治疗高血压的药物组合物
CA2695822A1 (en) A combination treatment
JP2005531492A (ja) 高リスク患者のｉｉ型糖尿病を低減させる方法
JP2024538054A (ja) 高シュウ酸尿症及び腎結石の治療のための１ｈ－１，２，３－トリアゾール－４－カルボン酸
Medoxomil et al. PrACT OLMESARTAN
JP2010513219A (ja) 腎臓の疾患、糖尿病性腎症及び脂質代謝異常の治療
EA047563B1 (ru) Канаглифлозин для лечения больных диабетом пациентов с хроническим заболеванием почек
MXPA04001174A (es) Tratamiento para lipodistrofia.
HK40015213A (en) Use of carbamate compounds for prevention, alleviation or treatment of bipolar disorder
WO2009046632A1 (en) Pharmaceutical composition containing angiotensin ii receptor blocker and b family vitamins and use thereof
TW201103544A (en) Pharmaceutical composition and application thereof

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: TRANSITION THERAPEUTICS IRELAND LIMITED

Free format text: FORMER APPLICANT(S): ELAN PHARMACEUTICALS, INC.

FGA Letters patent sealed or granted (standard patent)